News & Updates

HILPDA induces development of NASH-driven HCC

12 Aug 2023

Hepatic hypoxia-inducible lipid droplet associated protein (HILPDA) is predictive of survival in patients with nonalcoholic steatohepatitis (NASH)-driven hepatocellular carcinoma (HCC), according to a study.

HILPDA induces development of NASH-driven HCC

12 Aug 2023

Artificial sweeteners may be making people overweight

11 Aug 2023 by

A study links long-term intake of artificial sweeteners to fat accumulation, increasing the risk of obesity regardless of diet quality or caloric intake.

Artificial sweeteners may be making people overweight

11 Aug 2023

Global NAFLD incidence on the rise

11 Aug 2023

Current estimates of nonalcoholic fatty liver disease (NAFLD) incidence across the world show an increasing trend, with 4,613 new cases per 100,000 person-years, reveals a study.

Global NAFLD incidence on the rise

11 Aug 2023

Serum NGAL predicts AKI, mortality in patients presenting to ED

11 Aug 2023 by

Use of serum neutrophil gelatinase-associated lipocalin (NGAL) can help identify acute kidney injury and predict 3-month mortality among patients presenting to the emergency department (ED) with “normal” creatinine, reports a Singapore study.

Serum NGAL predicts AKI, mortality in patients presenting to ED

11 Aug 2023

Smartphone provides exact renditions of adult muscle mass

11 Aug 2023 by

Smartphones now have the capacity to accurately render an adult’s level of muscularity through their image capture capabilities in combination with device software applications, a recent study has shown.

Smartphone provides exact renditions of adult muscle mass

11 Aug 2023

DQI-5 effectively evaluates diet quality of preschoolers in SG

11 Aug 2023 by

Using data from the GUSTO* cohort, the DQI-5 – a Diet Quality Index developed for preschool-aged children – effectively assessed the diet quality of 5-year-olds in Singapore.

DQI-5 effectively evaluates diet quality of preschoolers in SG

11 Aug 2023

Add-on cabozantinib confers survival benefit in advanced renal-cell carcinoma with caveat

11 Aug 2023

For patients with treatment-naïve advanced renal-cell carcinoma who have intermediate or poor prognostic risk, adding cabozantinib to the combination of nivolumab and ipilimumab significantly prolongs progression-free survival (PFS) compared with the combination alone but at the expense of increased grade 3 or 4 adverse events (AEs), as shown in a phase III trial.

Add-on cabozantinib confers survival benefit in advanced renal-cell carcinoma with caveat

11 Aug 2023

Gene therapy may help reverse hereditary vision loss

11 Aug 2023 by

Experimental gene therapy appears to improve eyesight in patients with a severe progressive form of Leber’s hereditary optic neuropathy (LHON) in an early access programme.